7ON5

Crystal structure of the SARS-CoV-2 neutralizing nanobody Re5D06

7ON5 の概要

• エントリーDOI: 10.2210/pdb7on5/pdb
• 分子名称: Nanobody Re5D06, 1,2-ETHANEDIOL, ETHANOL, ... (4 entities in total)
• 機能のキーワード: neutralizing vhh, immune system
• 由来する生物種: Vicugna pacos
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 14462.90

構造登録者

Aksu, M.,Guttler, T.,Gorlich, D. (登録日: 2021-05-25, 公開日: 2021-08-11, 最終更新日: 2024-10-23)

主引用文献

Guttler, T.,Aksu, M.,Dickmanns, A.,Stegmann, K.M.,Gregor, K.,Rees, R.,Taxer, W.,Rymarenko, O.,Schunemann, J.,Dienemann, C.,Gunkel, P.,Mussil, B.,Krull, J.,Teichmann, U.,Gross, U.,Cordes, V.C.,Dobbelstein, M.,Gorlich, D.
Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Embo J., 40:e107985-e107985, 2021

PubMed Abstract: Monoclonal anti-SARS-CoV-2 immunoglobulins represent a treatment option for COVID-19. However, their production in mammalian cells is not scalable to meet the global demand. Single-domain (VHH) antibodies (also called nanobodies) provide an alternative suitable for microbial production. Using alpaca immune libraries against the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein, we isolated 45 infection-blocking VHH antibodies. These include nanobodies that can withstand 95°C. The most effective VHH antibody neutralizes SARS-CoV-2 at 17-50 pM concentration (0.2-0.7 µg per liter), binds the open and closed states of the Spike, and shows a tight RBD interaction in the X-ray and cryo-EM structures. The best VHH trimers neutralize even at 40 ng per liter. We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune-escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages. We also demonstrate neutralization of the Beta strain at low-picomolar VHH concentrations. We further discovered VHH antibodies that enforce native folding of the RBD in the E. coli cytosol, where its folding normally fails. Such "fold-promoting" nanobodies may allow for simplified production of vaccines and their adaptation to viral escape-mutations.

PubMed: 34302370
DOI: 10.15252/embj.2021107985

実験手法

X-RAY DIFFRACTION (1.25 Å)